Chiauranib for advanced cancers that returned or won’t respond
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 study tests chiauranib in people with advanced solid cancers (including small cell lung cancer) that have come back or no longer respond to standard treatments. It aims to find a safe dose and see whether the treatment can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older, and you have an advanced solid cancer that has returned or is resistant to standard treatment (or there’s no standard option).
- Your scans show at least one measurable tumor spot (a measurable lesion) that can be tracked over time.
- Your general health is good enough for treatment (ECOG 0–1).
- Your blood counts and organ function are strong: acceptable white blood cells, platelets, kidney function, liver tests, and blood clotting (with no major blood support or growth-factor medicines right before enrollment).
- You must have enough time to be in the study (life expectancy of at least 3 months) and be able to sign consent.
- If you can become pregnant, you must use very reliable birth control during treatment and for 12 weeks after the last dose; if you’re male, you must use condoms and ensure your partner is protected for the same period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
This Phase 2 trial tests 3D185 used alone for people with cholangiocarcinoma (bile duct cancer) that has grown despite earlier cancer treatment. It also looks at whether it’s safe and effective for tumors with certain FGF/FGFR gene changes.
This is an early-stage trial testing a new drug called CS231295 in people with advanced cancers (like lung, pancreatic, or brain tumors) that have stopped responding to standard treatments. The study aims to find the right dose and learn how well the drug works.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.